Skip to content

Bevacizumab exposure: adult and pediatric reference profiles

Compare constructed two-compartment bevacizumab exposure profiles across the released adult and pediatric reference cases. These fixed profiles do not simulate a mechanistic pediatric PBPK bridge.

Utilizing Minimal Physiologically Based Pharmacokinetic Modeling to Bridge Bevacizumab Pharmacokinetics from Adult to Pediatric Patients ↗

The AAPS Journal

Exploration notes · What are you exploring?

Notes stay on this browser.

MODEL IN MOTION 18 sec

How do adult and young-child bridge assumptions change drug amount?

Run settings

Run location

Explore this model

Choose a scenario, adjust inputs, and run the simulation.

Constructed fixed profile F-adult: 62 kg, 10 mg/kg q2w

Constructed fixed two-compartment profile with supplied apparent volumes, effective clearance and explicit central mg infusions; no physiological age or individual clinical prediction.

0–3,024 hour

Scenario details

Constructed fixed profile F-adult: 62 kg, 10 mg/kg q2w

Constructed fixed two-compartment profile with supplied apparent volumes, effective clearance and explicit central mg infusions; no physiological age or individual clinical prediction.

Readouts

Central conc · mg/L
Named conditional PK state, observer or diagnostic; units as declared.
Exposure (AUC) · mg*h/L
Named conditional PK state, observer or diagnostic; units as declared.
Eliminated · mg
Named conditional PK state, observer or diagnostic; units as declared.
Accounted drug · mg
Named conditional PK state, observer or diagnostic; units as declared.

Study purpose

  • How do the model's key biological readouts change under constructed fixed profile f-adult: 62 kg, 10 mg/kg q2w?

Assumptions

  • Interpret patterns within this model and starting configuration; do not treat them as clinical predictions or treatment recommendations.

Inputs changed since the displayed result. Run to update the comparison.

Loading starting example…

Edit inputs

Simulation time
h
h
3024 → 168

Time between reported samples.

h
4 → 1

2 changes · Variation 1

Continue in the background and keep the result.

Biology

Constructed fixed two-compartment bevacizumab profiles with specified central mg infusions, effective constant clearance, apparent distribution and physical accounting.

Constructed fixed two-compartment bevacizumab profiles with specified central mg infusions, effective constant clearance, apparent distribution and physical accounting.

Model details

6 parameters · 5 states · 5 equations · 20 derived outputs

Classification & API access
Therapeutic
Bevacizumab
Modality
Monoclonal antibody
Target
VEGF-A
Disease / scope
Pediatric-to-adult bevacizumab exposure bridging
ParameterDefaultUnitDescription
Additional clearanceCLadd_L_h0.00278L/hSupplied fixed effective two-compartment coordinate; physical role and construction are explicitly declared. Not an editable or original physiological source-model coefficient domain.
Catabolic clearanceCLcat_L_h0.0175L/hSupplied fixed effective two-compartment coordinate; physical role and construction are explicitly declared. Not an editable or original physiological source-model coefficient domain.
Body weightbody_weight_kg70kgSupplied fixed effective two-compartment coordinate; physical role and construction are explicitly declared. Not an editable or original physiological source-model coefficient domain.
Central volumecentral_volume_l_per_kg0.052L/kgSupplied fixed effective two-compartment coordinate; physical role and construction are explicitly declared. Not an editable or original physiological source-model coefficient domain.
Peripheral volumeperipheral_volume_l_per_kg0.04L/kgSupplied fixed effective two-compartment coordinate; physical role and construction are explicitly declared. Not an editable or original physiological source-model coefficient domain.
Intercompartmental clearanceq_l_h0.02L/hSupplied fixed effective two-compartment coordinate; physical role and construction are explicitly declared. Not an editable or original physiological source-model coefficient domain.

Related models

Bevacizumab and VEGF165 conditional QSS bindingFixed-weight antibody PK and driven-target referenceDupilumab exposure and atopic-dermatitis responseEnfortumab vedotin and MMAE concentration-input reference

Feedback: helpdesk@unibiointelligence.com.

Ubi Biologics